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AbstrACt
Introduction Each year in the UK over 120 000 people 
fracture their ankle. It is not known what the best 
rehabilitation strategy is for these people. Traditionally 
standard care has involved immobilisation in a plaster 
cast but an alternative is a functional brace, which can be 
removed to allow early movement. This paper details the 
protocol for a multicentre randomised trial of plaster cast 
immobilisation versus functional bracing for patients with 
an ankle fracture.
Methods and analysis We will recruit adults with a 
fractured ankle, for which the treating clinician would 
consider plaster cast to be a reasonable management 
option. Randomisation will be on a 1:1 basis, stratified 
by centre, operative or non-operative management and 
age. Participants will be allocated to either plaster cast 
or a functional brace, both treatments are widely used. 
To have 90% power to detect a difference of 10 points on 
the primary outcome (Olerud and Molander Ankle Score) 
at the primary outcome time point (16 weeks), we need to 
randomise a minimum of 478 people. Quality of life and 
resource use will be collected at 6, 10, 16, 24 weeks and 
12, 18, 24 months. The differences between treatment 
groups will be assessed on an intention-to-treat basis. The 
economic evaluation will adhere to the recommendations 
of the National Institute for Health and Care Excellence 
reference case.
Ethics, registration and dissemination National 
Research Ethic Committee approved this study on 4 July 
2017 (17/WM/0239). The first site opened to recruitment 9 
October 2017. The results of this trial will be submitted to 
a peer-reviewed journal and will inform clinical practice.
trial registration number ISRCTN15537280; Pre-results. 
IntroduCtIon 
Nine per cent of trauma surgeons’ work-
load in the UK is managing ankle fractures; 
over 120 000 per year in the UK. A threefold 
increase is expected by 2030 due to an increase 
in older adults who are remaining physically 
active.1 2 The frequency of this injury is an 
increasing burden on the National Health 
Service (NHS) year on year.3 The short-
term impact of this injury results in physical 
impairments of pain, stiffness, weakness and 
swelling. The longer term impact results in 
extended time off work and development of 
post-traumatic arthritis.4 5 
Management has traditionally included 
plaster cast immobilisation for several 
weeks, while the bone heals. A cast provides 
maximum support, however, there are poten-
tial problems, there are the risks associated 
with prolonged immobilisation such as muscle 
atrophy, deep vein thrombosis and joint stiff-
ness. There are the long-term consequences, 
which include prolonged gait abnormali-
ties, persistent calf muscle weakness and an 
inability to return to previous activity levels. 
Functional bracing may address these issues.6 
However, it does not provide the same degree 
of support to the healing bones.5 7
A research priority exercise was under-
taken by a UK orthopaedic group in 2010.8 
One of the top priority questions was to estab-
lish whether there is a functional advantage 
associated with different rehabilitation plans 
following an ankle fracture. This was followed 
by a 2012 Cochrane review9 which identi-
fied the need for further research into the 
strengths and limitations of this study
 ► Broad eligibility criteria to ensure results can be 
generalised to the wider population.
 ► UK-wide trial across a minimum of 19 centres to op-
timise external validity.
 ► Primary outcome measure is patient centred.
 ► Blinding of interventions is not possible.
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optimal method of immobilisation for both operatively 
and non-operatively managed acute ankle fractures. This 
issue was raised again in a James Lind Alliance Priority 
Setting Partnership in 2018, which included: ‘What is the 
best physiotherapy regimen for adults during out-of-hos-
pital recovery from a fragility fracture of the lower limb?’ 
in its top 10 priority research questions.10
Good ClInICAl PrACtICE
The trial will be conducted in full conformance with the 
principles of the Declaration of Helsinki and to Good 
Clinical Practice guidelines and comply with UK legisla-
tion and Warwick standard operating procedures (SOPs). 
All data will be stored securely and held in accordance 
with applicable data protection legislation.
ConsolIdAtEd stAndArds of rEPortInG trIAls
The trial will be reported in line with the Consolidated 
Standards of Reporting Trials (CONSORT) statement 
using the non-pharmacological treatment interventions 
extension.
AIM
Our aim is to determine which of two immobilisation 
strategies for people with a fractured ankle is superior.
objECtIvEs
Primary objective
To quantify and draw inferences on observed differ-
ences in the Olerud and Molander Ankle Score (OMAS) 
between functional brace and plaster cast treatment 
groups 16 weeks after randomisation.
Secondary objectives
1. To quantify and draw inferences on observed differ-
ences in ankle function assessed using the OMAS score 
at 6 weeks, 10 weeks, 24 weeks and 24 months and 
Manchester-Oxford Foot Questionnaire (MOXFQ) 16 
weeks after randomisation.
2. To draw inferences on the observed differences in an-
kle function assessed using the OMAS scores in opera-
tive and non-operative subgroups.
3. To draw inferences on the observed differences in an-
kle function assessed using the OMAS scores in those 
50 years of age and over and those 49 years of age and 
under subgroups.
4. To quantify and draw inferences on observed differ-
ences in health-related quality of life (EuroQOL-five 
dimensions five-level, EQ-5D-5) between trial treat-
ment groups at 6 weeks, 10 weeks, 16 weeks, 24 weeks, 
12 months, 18 months and 24 months after randomi-
sation.
5. To quantify and draw inferences on observed differ-
ences in Disability Rating Index (DRI) between trial 
treatment groups at 6 weeks, 10 weeks, 16 weeks, 24 
weeks and 24 months after randomisation.
6. To quantify and draw inferences on observed differ-
ences on complication rates between trial treatment 
groups at 6 weeks, 10 weeks, 16 weeks, 24 weeks and 24 
months after randomisation.
7. To estimate comparative cost–utility of the two tri-
al treatment groups and collect resource use data at 
6 weeks, 10 weeks, 16 weeks, 24 weeks, 12 months, 18 
months and 24 months after randomisation.
MEthods And AnAlysIs
study design
This is a UK multicentre two arm parallel group 
randomised controlled trial.
sample size
The primary outcome for this study is the OMAS 16 weeks 
postinjury. The OMAS is measured on a scale between 0 
and 100, where higher scores denote better function. We 
are seeking to show a between-group difference of 10 
points. This is consistent with the Ankle Injury Manage-
ment (AIM) study,11 which set the OMAS equivalence 
margin between groups to be 6 points. It is also consistent 
with other similar outcome measures such as the Foot and 
Ankle Outcome Score,12 and Visual Analogue Pain Scores 
in acute injury; that set Minimally Clinically Important 
Difference (MCIDs) of approximately 10 points on a 100 
point scale in a trial context.
The SD of the OMAS from previous feasibility work 
was approximately 28 points. To account for any varia-
tion arising from recruiting from multiple study centres, 
we have selected a conservative estimation of the trial 
SD of 30 points. The total trial sample size required to 
detect a difference of 10 points given an SD of 30 points 
with two-sided significance set at 5% and 90% power is 
382 participants. Allowing a margin of 20% loss during 
follow-up, this gives a minimum figure of 478 participants. 
If possible, recruiting a larger sample would enable the 
between-group differences of the two groups to be esti-
mated with higher precision. The minimum 382 partic-
ipants would create a 95% CI of width 8.5 points. If, for 
example, 625 participants were recruited, this would yield 
data on around 500 participants at 20% lost to follow-up 
and would enable a 95% CI of width 7.4 points to be 
constructed. Given that both interventions are routinely 
used in clinical practice and are low risk, if recruitment 
rates are higher than expected then recruitment will 
continue to a predefined end recruitment date to allow 
greater precision.
outcome measures
Primary
OMAS is a self-administered questionnaire consisting 
of nine different items: pain, stiffness, swelling, stair 
climbing, running, jumping, squatting, supports and 
work/activities of daily living.13 These data will be 
 o
n
 18 January 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027242 on 18 December 2018. Downloaded from 
3Kearney RS, et al. BMJ Open 2018;8:e027242. doi:10.1136/bmjopen-2018-027242
Open access
collected at 6 weeks, 10 weeks, 16 weeks, 24 weeks and 24 
months after randomisation.
Secondary
EQ-5D-5L is a validated, generic health-related quality 
of life measure consisting of five dimensions each with 
a five-level response. Each combination of answers is 
converted into a health utility score that has good test–
retest reliability, is simple for participants to use, and gives 
a single preference-based index value for health status 
that can be used for broader cost-effectiveness compar-
ative purposes.14 These data will be collected at 6 weeks, 
10 weeks, 16 weeks, 24 weeks, 12, 18 and 24 months after 
randomisation.
MOXFQ is a self-administered questionnaire that 
consists of 16 items, each with five response options 
comprising three separate underlying dimensions; 
walking/standing problems (seven items), foot pain 
(five items) and issues related to social interaction (four 
items). Item responses are each scored from 0 to 4, with 
4 representing the most severe state. The scale scores 
representing each dimension are calculated by summing 
the responses to each item within that dimension. Raw 
scale scores are then converted to a metric (0–100; 
100=most severe). These data will be collected at 16 weeks 
only.
DRI is a self-administered questionnaire. It consists 
of 12 items specifically related to function of the lower 
limb. The DRI has been proven to be a practical clinical 
and research instrument, with good responsiveness and 
acceptability for assessment of disability caused by impair-
ment in the lower limb.15 These data will be collected at 6 
weeks, 10 weeks, 16 weeks, 24 weeks and 24 months after 
randomisation.
Complications will be captured through two mecha-
nisms. First, participants will be asked on each follow-up 
questionnaire collected at 6 weeks, 10 weeks, 16 weeks, 24 
weeks, 12, 18 and 24 months after randomisation. Second, 
sites will be asked to report complications during the 
follow-up period to the central trial team. All prereduc-
tion baseline X-ray/radiographs and also the last X-ray/
radiograph taken before the primary outcome point of 
16 weeks will be collected as part of the complication data 
set.
The primary analysis will concentrate on direct inter-
vention and healthcare/personal social services costs, 
while wider impact (societal) costs will be included 
within the sensitivity analyses. Relevant resource use 
questionnaires will be administered to participants at 
baseline and all follow-up points, to collect resource 
use data associated with the interventions under 
examination. These data will be collected at 6 weeks, 
10 weeks, 16 weeks, 24 weeks, 12, 18 and 24 months 
after randomisation.
screening and eligibility
UK NHS trust sites will be used to screen all adults with 
a closed ankle fracture (within 3 weeks of operative 
management or injury if non-operative) which the treating 
clinician would consider plaster cast a reasonable manage-
ment option will be screened by clinical care. Screening 
logs will be collected to assess the main reasons for exclu-
sion as well as number of people unwilling to take part.
Inclusion criteria
1. Able to give written informed consent.
2. Aged 18 years or over.
3. A closed ankle fracture for which the treating clinician 
would consider plaster cast a reasonable management 
option.
4. Randomised within 3 weeks of operative management 
or injury if non-operative.
Exclusion criteria
1. Ankle fracture secondary to known metastatic disease.
2. Complex intra-articular fracture (eg, pilon fracture).
3. In the opinion of the surgeon the patient would re-
quire manipulation and close contact/moulded cast-
ing.
4. Wound complications contraindicating functional 
brace intervention.
5. Known pre-existing neuropathic joint disease contrain-
dicating functional brace intervention.
6. Previous ankle fracture already randomised in the 
present trial.
7. Unable to adhere to trial procedures or complete post-
al questionnaires.
Consent
Potential participants will be provided with verbal and 
written information about the study. Written informed 
consent will be obtained by a member of the research 
team at each site. The right of a potential participant 
to refuse participation without giving reasons will be 
respected, and recorded on the screening log. The 
participant will remain free to withdraw at any time 
without giving reasons and without prejudice to any 
further treatment, and will be provided with a contact 
point where he/she may obtain further information 
about the trial.
At the point of initial consent, participants will be asked 
if they consent to be contacted for any future research 
related to their ankle fracture. Those who consent will 
be provided with additional verbal and written informa-
tion about appropriate additional studies related to their 
ankle fracture.
randomisation
Subjects will be randomised in ratio of 1:1 to the two study 
intervention arms strictly sequentially, as they become 
registered as eligible for randomisation on a secure pass-
word-protected web-based system. Allocation concealment 
will be maintained by an independent randomisation 
team, at the accredited clinical trials unit (CTU), who will 
be responsible for generation of the sequence and will 
have no role in the allocation of participants.
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The treatment group will be allocated by computer 
using a minimisation algorithm with a random 
element and stratification by centre, age and oper-
ative/non-operative management following use of a 
secure web-based randomisation service. The rando-
misation system will allocate each participant a unique 
trial number.
Stratification by centre will help ensure that any clus-
tering effect related to the centre itself will be equally 
distributed in the trial arms. Stratification on the basis of 
age will be used to ensure that younger participants with 
normal bone quality sustaining high-energy fractures and 
older participants with low-energy (fragility) fractures 
related to osteoporosis are balanced between arms. The 
age group stratification will be used as a proxy for bone 
density. Based on previous literature, this will be set at 
those 49 years and under and those 50 years and over.1 16 
A final stratification based on operative/non-operative 
presentation will be implemented.
Postrandomisation withdrawals
Unless a participant explicitly withdraws their consent, 
they will be followed up and data collected as per the 
protocol until the end of the trial. For participants explic-
itly withdrawing consent for follow-up procedures, trial 
data obtained up until the point of withdrawal will be 
included in the final analysis of the study. Participants will 
have the option to withdraw from the trial-related ques-
tionnaires, but continue to provide routine NHS data for 
the purposes of the trial, for example, hospital records 
of subsequent treatment for the ankle fracture. Partici-
pants who withdraw will not be replaced. Participants may 
also be withdrawn from the trial at the discretion of the 
investigator and/or trial steering committee (TSC) due 
to safety concerns.
Interventions
All participants who require ankle fixation will have this 
performed according to the preferred technique of the 
operating surgeon, details of the procedure undertaken 
will be recorded. All participants will then receive normal 
local care until satisfactory clinical wound check (usually 
2 weeks postoperatively, up to maximum 3 weeks), at 
which point the intervention will be applied by a member 
of the trauma team.
All participants not undergoing surgery will be 
approached to take part in the trial on first presentation 
to the trauma team fracture clinic, and will be eligible 
for trial participation up to a maximum of 3 weeks from 
injury. Weight-bearing status will be at the discretion of 
the treating member of the trauma team and recorded on 
subsequent case report forms (CRFs).
Control group: standard plaster cast
Participants will be fitted with cast immobilisation for a 
minimum of 3 weeks. It is expected that the control interven-
tion will not exceed 8 weeks, however, this will be recorded 
and monitored by the trial management group (TMG). The 
details of the plaster cast material and method of applica-
tion will be at the discretion of the treating clinician as per 
local procedures. Once the cast is removed, participants will 
be encouraged to complete active unloaded ankle range of 
movement exercises, as per routine clinical practice.
Intervention group: functional bracing
Participants will be fitted with a functional brace (A fixed 
angle design was specified but the brand and manufac-
turer was at the discretion of the local site) for a minimum 
of 3 weeks. It is expected that the intervention will not 
exceed 8 weeks, however, this will be recorded and moni-
tored by the TMG. Throughout this period participants 
will be encouraged to remove their functional brace to 
complete active unloaded ankle range of movement exer-
cises, little and often as pain allows. An information sheet 
explaining these exercises will be handed out to all partic-
ipants randomised to this trial arm.
rehabilitation
Any other rehabilitation input will be left to the discretion 
of the treating trauma team member. However, a record 
of any additional rehabilitation, together with a record 
of any other interventions will be recorded on follow-up 
CRFs.
blinding
The participants cannot be blind to their treatment. The 
treating clinical team cannot be blind either, but will take 
no part in the assessment of participants.
All questionnaire data will be collected via phone and 
postal mechanisms and entered onto the trial central data-
base by a member of the research team, who cannot be 
blinded to the trial interventions. Data will be presented 
to the data monitoring committee (DMC) using a combi-
nation of open and closed reports that will be further 
detailed in the statistical analysis plan.
Adverse event management
Adverse events will be listed on CRF for return to the 
‘AIR’ central office. Serious adverse events (SAEs) will 
be entered onto the SAE reporting form and reported 
to the central study team. All participants experiencing 
SAEs will be followed up as per protocol until the end of 
the trial. All SAEs that occur between date of consent and 
24-month follow-up point will be reported to the sponsor 
(University of Warwick), ethics committee and oversight 
committees.
Patient and public involvement
Patients were consulted to ascertain if the research gaps 
highlighted by peer-reviewed literature were of impor-
tance from their perspective. Based on these responses 
a single site feasibility trial was developed and funded 
by National Institute for Health Research (NIHR) 
(ISRCTN17809322). The feasibility trial team involved 
two patient and public involvement representatives, who 
continued their roles through to planning, development 
and delivery of the current main trial. Specifically, they 
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have been active members on the TMG, reviewed consent 
procedures and developed patient facing study mate-
rials. At the end of the study, they will be vital to dissem-
ination plans, which include the development of a lay 
summary of findings to be distributed through a variety 
of resources such as the trial website and posted directly 
to trial participants.
End of trial
The trial will end when all participants have completed 
their 24-month follow-up. The trial will be stopped prema-
turely if mandated by the ethics committee, following 
recommendations from relevant oversight commit-
tees or funding for the trial ceases. The research ethics 
committee will be notified in writing within 90 days when 
the trial has been concluded or within 15 days if termi-
nated early.
trial oversight
Trial management group
The TMG, consisting of the project staff and coinvestiga-
tors involved in the day-to-day running of the trial, will 
meet monthly throughout the project. Significant issues 
will be referred to the TSC or Investigators, as appropriate.
Trial steering committee
The TSC will have an independent chairperson and 
consist of clinicians, methodologists and lay representa-
tion. Meetings will be held not less than once a year. The 
TSC will take responsibility for approval of the protocol, 
major decisions (eg, need to change the protocol)l, moni-
toring progress of the trial, reviewing relevant informa-
tion from other sources, considering recommendations 
from the DMC, informing and advising on all aspects of 
the trial.
Data monitoring committee
The DMC will consist of independent members with rele-
vant clinical research and statistical expertise. The DMC 
meeting frequency will be guided by the DMC chair, but 
with a plan to be 6 months into the recruitment phase 
and regularly thereafter. Confidential reports containing 
recruitment, protocol compliance, safety data and 
interim assessments of outcomes will be reviewed by the 
DMC. The DMC will advise the TSC as to whether there 
is evidence or reason why any trial procedures should be 
modified or the study terminated.
Quality control
Quality assurance checks to ensure integrity of randomi-
sation, study entry procedures and data collection will 
follow Warwick CTU SOPs.
statistical analysis plan
Treatment effects will be presented, with appropriate 
95% CIs, for both the unadjusted and adjusted analyses. 
Tests will be two sided and considered to provide evidence 
for a significant difference if p values are less than 0.05 
(5% significance level). All analyses will be conducted 
as intention to treat unless otherwise specified. No 
interim analyses are planned and interim analyses will be 
performed only where directed by the DMC, and with the 
agreement of the TSC.
Baseline data will be summarised to check compa-
rability between treatment arms, and screening data 
will be checked to highlight any characteristic differ-
ences between those individuals in the study, and those 
eligible but withholding consent. A CONSORT chart 
illustrating participant flow throughout the study will 
also be produced. Standard statistical summaries will be 
presented for the primary outcome measure (OMAS) 
and all secondary outcome measures.
The main analysis will investigate differences in the 
primary outcome measure, 16 weeks after randomisa-
tion, between the two treatment groups. Unadjusted and 
adjusted regression analyses will be used to estimate the 
between-group difference. The adjusted analyses will 
adjust for the stratification variables, baseline scores and 
any other clinically important variables. More specifically, 
adjusted mixed-effects modelling will be used where the 
recruiting centre will be included as a random effect 
to allow for possible heterogeneity in patient outcomes 
due to the recruiting centre. Since individual clinicians 
will treat only a small number of participants enrolled in 
the trial, we do not expect clinician-specific effects to be 
important in this study and hence will not be modelled. 
This adjusted mixed-effects linear regression analysis 
will be reported as the primary analysis, and will be used 
to assess evidence for differences in outcomes between 
intervention arms.
Descriptive statistics of patient-reported outcome 
measure (PROM) data (ie, OMAS, MOXFQ, EQ5D and 
DRI) at each time point will be calculated with between-
group analyses following the method set out for the 
primary analysis above. Patterns of recovery will also be 
explored. For example, the area under the curve for 
PROM data will be estimated using the trapezoidal rule 
for each allocation arm.
Complications will be summarised with between-groups 
comparisons evaluated using X2 tests. Temporal patterns 
of any complications will be presented graphically and if 
appropriate, a time-to-event analysis (eg, Kaplan-Meier 
survival analysis) will be used to assess the overall risk and 
risk within individual classes of important complications 
(eg, non-union).
Two prespecified subgroup analyses will be undertaken 
to assess whether there is evidence that the intervention 
effect differs between whether the study participants 
receives operative or non-operative treatment prior to the 
study intervention and study participants are aged 50 or 
over at study randomisation.
The subgroup analyses will follow the methods described 
for the primary analysis, with additional interaction terms 
incorporated into the mixed-effects regression model 
to assess the level of support for these hypotheses. The 
study is not powered to formally test these hypotheses, so 
they will be reported as exploratory analyses only, and as 
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subsidiary to the analysis reporting the main effects of the 
intervention in the full study population.
Some data may not be available due to voluntary with-
drawal of participants, lack of completion of individual 
data items or general lost to follow-up. Where possible 
the reasons for data ‘missingness’ will be ascertained and 
reported. The nature and pattern of the missingness will 
be carefully considered, including whether data can be 
treated as missing completely at random. If judged appro-
priate, missing data will be imputed using the multiple 
imputation facilities available in the statistical analysis 
software.
If imputation is undertaken, the resulting imputed data-
sets will be analysed, together with appropriate sensitivity 
analyses. Any imputation methods used for scores and 
other derived variables will be carefully considered and 
justified. Reasons for ineligibility, non-compliance, with-
drawal or other protocol violations will be stated and any 
patterns summarised. More formal analysis, for example, 
using logistic regression with ‘protocol violation’ as a 
response, may also be appropriate and aid interpretation.
health economic analysis plan
Prospective economic evaluation, conducted from an 
NHS and personal social services perspective, will be 
included. The economic evaluation will estimate the 
difference in the cost of resource inputs between the two 
intervention groups, enabling costs and consequences 
to be compared. The methods will adhere to the recom-
mendations of the National Institute for Health and Care 
Excellence (NICE) reference case.17
Primary research methods will be followed to estimate 
the costs of the treatment options, including resource 
inputs associated with the plaster materials and braces, 
supplementary interventions, adverse events and rehabili-
tation inputs. Broader resource utilisation associated with 
the ankle injury will be captured through routine health 
service data collection systems and participant question-
naires administered at each follow-up time point.
Unit costs will be estimated from local and national 
sources in addition to primary research using estab-
lished accounting methods. Costs will be standardised to 
current prices where possible. Health-related quality of 
life will be measured at the time of consent, and all follow 
time points using the EQ-5D-5L measure. Responses will 
be used to generate quality-adjusted life years (QALYs) 
using the UK time-trade-off value set recommended by 
the EQ group.18
Within-trial analysis using bivariate regression of costs 
and QALYs, with multiple imputation of missing data, will 
inform a probabilistic assessment of incremental treat-
ment cost-effectiveness from a health service perspective. 
Missingness mechanisms will be explored and multiple 
imputation methods will be used where appropriate 
to avoid biases associated with complete case analysis. 
Costs and outcomes arising after the first year of the trial 
will be discounted at 3.5%. Sensitivity analyses will be 
undertaken to explore uncertainty on the incremental 
cost-effectiveness ratios and to consider issues of general-
isability of the study.
More extensive economic modelling using decision-an-
alytical methods may be considered to extend the target 
population, time horizon and decision context, drawing 
on the best available information from the literature and 
stakeholder consultations to supplement the trial data. 
Parameter uncertainty in the decision-analytical model 
will be explored using probabilistic sensitivity analysis. 
Longer term costs and consequences will be discounted 
to present values using discount rates recommended for 
health technology appraisal in the UK (current discount 
rate: 3.5%).
Ethics and dissemination
Both functional brace and plaster interventions are 
currently used across the NHS for the management of 
ankle fractures. Consequently, both trial interventions 
reflect current standard practice and do not expose trial 
participants to any substantial risks over and above stan-
dard care currently received.
The results of the trial will be reported first to trial 
collaborators. The main report will be drafted by the trial 
coordinating team, and the final version will be agreed by 
the TSC before submission for publication, on behalf of 
the collaboration. The trial will be reported in accordance 
with the CONSORT (http://www. consort- statement. org).
The results of this project, full protocol and related 
documentation will be disseminated through the trial 
website, peer-reviewed journals, conference presentations 
among the orthopaedic and rehabilitation networks, the 
National Library for Health, policy-makers such as NICE, 
patient-specific newsletters and through local mecha-
nisms at all participating centres.
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